NSD1 loss decreases the growth of liver, breast and esophageal cancer cells (15–17), and NSD1 depletion leads to a moderate increase in sensitivity to cisplatin and carboplatin drugs (12, 13). Here, NSD1 is linked to esophageal cancer.